SPX4,026.12-1.14 -0.03%
DIA343.52+1.57 0.46%
IXIC11,226.36-58.96 -0.52%

BRIEF-Monopar Announces Encouraging Clinical Data From Ongoing Camsirubicin Phase 1B Trial

Reuters · 11/16/2022 07:03
BRIEF-Monopar Announces Encouraging Clinical Data From Ongoing Camsirubicin Phase 1B Trial

- Monopar Therapeutics Inc MNPR.O:

  • MONOPAR ANNOUNCES ENCOURAGING CLINICAL DATA FROM ONGOING CAMSIRUBICIN PHASE 1B TRIAL

  • MONOPAR ANNOUNCES ENCOURAGING CLINICAL DATA FROM ONGOING CAMSIRUBICIN PHASE 1B TRIAL

  • MONOPAR THERAPEUTICS INC - NO DRUG-RELATED CLINICAL CARDIOTOXICITY HAS BEEN OBSERVED IN ANY PATIENT

  • MONOPAR THERAPEUTICS INC - TRIAL IS CONTINUING TO ENROLL AND DOSE-ESCALATE, AS THERE HAVE BEEN NO SIGNS OF HAVING YET HIT MAXIMUM TOLERATED DOSE

Source text for Eikon: ID:

Further company coverage: MNPR.O


((Reuters.Briefs@thomsonreuters.com;))